1 active not recruiting, 1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Atropine: new trials by email Literature Review of Atropine trials Research Report on Atropine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NMBA Reversal and Postoperative Urinary Retention Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist]) - Neuromuscular Blocking Agents, Urinary Retention After Procedure | Active not recruiting | Beth Israel Deaconess Medical Center | 70000 | 2025-06-08 | 2026-01-23 | |
| Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression Atropine sulphate eye drop 0.01%, Atropine sulphate eye drop 0.03%, Atropine sulphate eye drop 0.05% - Myopia Progression, Atropine | Phase 3 | Completed | Khyber Medical College, Peshawar | 95 | 2024-06-03 | 2026-06-10 |
Myopia (1) · Myopia, Degenerative (1) · Urinary Retention (1)
Eye Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Refractive Errors (1) · Urination Disorders (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Neostigmine (1) · Sugammadex (1)
Beth Israel Deaconess Medical Center (1) · Khyber Medical College, Peshawar (1)
Pakistan (1) · United States (1)
Luca J Wachtendorf, MD (1) · Maximilian S Schaefer, MD, PhD (1) · Nazli Gul, FCPS (1)